Tacrolimus, a heterocyclic macrolide immunosupressive agent that belongs to the calcineurin inhibitor class, works by blocking the production of IL-2, thereby inhibiting proliferation of antigenspecific T lymphocytes. 1 It is estimated to be 50-200 times more potent than cyclosporin (CYA) and is now commonly used after allo-SCT to prevent GVHD. 1 Although common adverse effects like hypertension, nephrotoxicity and hyperglycemia are manageable without drug discontinuation, serious adverse effects might require discontinuation and change to an immunosuppressive agent from a different class. 1 Reported incidence of neurotoxicity from tacrolimus may be as high as 32%. 2 Most common neurologic side effects include tremor, insomnia, nightmares, headache, vertigo and mood disturbance. Serious neurologic adverse effects are relatively rare and include: seizures, cortical blindness, coma or encephalopathy. 2 Here we present an uncommon but serious neurological complication of tacrolimus: akinetic mutism, mostly described in solid organ transplantation. [3] [4] [5] [6] [7] [8] This case documents the occurrence of akinetic mutism after hematopoietic SCT.
A 58-year-old woman without significant medical history except primary refractory AML was admitted to the hospital for a haploidentical stem cell transplant from her son. Conditioning chemotherapy consisted of fludarabine 160 mg/m 2 , melphalan 140 mg/m 2 and thiothepa 10 mg/kg. The patient received post transplant CY 50 mg/m 2 on days þ 3 and þ 4 for GVHD prophylaxis followed by tacrolimus 0.7 mg intravenous (i.v.) and mycophenolate 2.25 g daily, which started on day 5. The tacrolimus dose was adjusted to 1.4 mg daily, which maintained the serum tacrolimus level in the therapeutic range (6-15 ng/mL). On day 16, the patient started to develop poor motivation to continue her post-transplant recovery and became increasingly withdrawn. She was evaluated by psychiatry and it was appreciated that her symptoms were not related to depression or other psychiatric condition. During the next several days her symptoms worsened. She developed extreme apathy, low energy, poor concentration and somnolence. TSH and free T4 were normal. An Electroencephalogram (EEG) was performed, which showed findings of mild generalized slowing with sleep patterns. Possible sedating medications were discontinued; however, her symptoms continued to worsen. She developed mutism with inability to answer any questions or have spontaneous speech, as well as inability to perform any voluntary movements. She appeared to understand but was unable to communicate or follow commands. No overt metabolic abnormalities were found by laboratory evaluation. Methylphenidate was tried for a short period of time with no improvement. When symptoms started her tacrolimus level was 10.9 ng/mL. She had no focal neurological deficits and an MRI brain showed scattered T2/FLAIR (fluidattenuated inversion recovery) hyperintensities in the periventricular and deep white matter, and no acute intracranial pathology. A lumbar puncture was performed and the cerebrospinal fluid showed normal WBC count, elevated RBC count at 40/UL (0-0 U/L), elevated glucose at 93 mg/dL (40-70 mg/dL) and elevated protein at 74 mg/dL (15-55 mg/dL). All the bacterial and viral infectious studies were negative. The patient was empirically started on forscarnet for possible viral encephalitis without improvement. Her symptoms persisted, and on day 36 her tacrolimus, which had always been in the therapeutic range, was discontinued, due to possible neurotoxicity. She was started on sirolimus, and the mycophenolate was continued. On day 37 the patient developed tremors, a repeat EEG showed unspecific findings. Because epileptiform waves could not be excluded, she was empirically started on i.v. dilantin for possible non-convulsive status epilepticus requiring intensive care unit admission and intubation for airway protection. Her clinical course was complicated by hypotension and acute kidney injury, and she received hemodyalisis transiently. On day 43 she was extubated, slowly started again to communicate, and become more interactive with spontaneous movements and speech. She had no recollection of previous events. Upon discharge from the hospital, she was fully interactive and had no neurologic deficits.
Tacrolimus-induced akinetic mutism is an uncommon but serious complication, described in solid organ transplant patients, [3] [4] [5] [6] [7] [8] and only in one stem cell transplant patient. 9 It has been shown that this adverse effect can develop even with therapeutic levels of tacrolimus 2, 4, 6 and can lead to tonic clonic seizures 3, 5 after mutism has occurred. 3 The etiology is unknown, but it is hypothesized that tacrolimus might cause breakdown of the auto-regulation in the blood-brain barrier by inducing vasogenic edema from enhanced nitric oxide production causing endothelial damage. 7, 9 Another theory is that neutoxicity can occur from changes in central nervous system neurotransmitters, 2,4,5 as tacrolimus can modulate the activity of both excitatory (N-methyl-D-aspartic acid (NMDA)) and inhibitory (gamma-aminobutyric acid (GABA)) aminoacid receptors via calcineurin. 1 Abnormalities on imaging are sometimes seen in this disorder. In some cases, MRI brain has shown non-specific cerebellar or cerebral white and gray matter changes 3, 7, 8 and in one report, changes were seen on Positron emission tomography scan 4 consisting of decrease FDG (Fluodeoxyglucose) uptake in the temporal lobes and adjacent parieto-occipital regions bilaterally.
The most often used treatment is discontinuation of tacrolimus [2] [3] [4] [5] and replacement with an alternate immunosuppressive agent like mycophenolate mofetil or sirolimus. In one report clinical improvement was noted after administration of lorazepam,
